

Fax

To: Timothy Cole/ GAU: 1713 **From:** Yu-An Chang & Jim-Son Chou, applicants
Fax: 571-273-8300 **Pages:** 11
Phone: 571-272-0999 **Date:** December 21, 2005
Re: Application Ser. No. 10/688,757 **Tel:** 949-857-8960 or 949-294-6458

Certificate of Transmission under 37 CFR 1.8

**We hereby certify that this correspondence is being facsimile transmitted to the
United States Patent and Trademark Office**


Transmittal:

- (1) Amendment B in 4 pages signed Declaration by Inventors and listing of claims;
- (2) "Clean Copy" of patent application with currently amended Claims, in 2 pages;
- (3) "Mark up copy" of the Original application claims with proper markings in 2 pages;
- (4) A copy of Office communication dated 12/2/2005 from Examiner Timothy Cole, in 3 pages.

In this corrected file:

- (1) A list of original claims and currently amended claims with proper status identifier. Each claim in the original application has been provided with the proper marking.
- (2) Mistakes mentioned in the US Patent Office communication have been corrected following the advices of the patent examiner.

On 12/22/05
Date


Signature

Yu-An Chang

Jim-Son Chou

(Applicants)

Typed or printed names of persons signing Certificate

Continuation of 4(e) Other: Status identifiers should be present after each claim number. Markings and/or underlining were not presented with amended claims.

RECEIVED
CENTRAL FAX CENTER
DEC 23 2005

Notice of Non-Compliant Amendment (37 CFR 1.121)	Application No.	Applicant(s)
	10/688,757	CHANG ET AL
	Examiner	Art Unit
	Timothy Cole	1700

— The MAILING DATE of this communication appears on the cover sheet with the correspondence address —

The amendment document filed on 25 November 2005 is considered non-compliant because it has failed to meet the requirements of 37 CFR 1.121. In order for the amendment document to be compliant, correction of the following item(s) is required.

THE FOLLOWING MARKED (X) ITEM(S) CAUSE THE AMENDMENT DOCUMENT TO BE NON-COMPLIANT:

- 1. Amendments to the specification:
 - A. Amended paragraph(s) do not include markings.
 - B. New paragraph(s) should not be underlined.
 - C. Other _____.
- 2. Abstract:
 - A. Not presented on a separate sheet. 37 CFR 1.72.
 - B. Other _____.
- 3. Amendments to the drawings:
 - A. The drawings are not properly identified in the top margin as "Replacement Sheet," "New Sheet," or "Annotated Sheet" as required by 37 CFR 1.121(d).
 - B. The practice of submitting proposed drawing correction has been eliminated. Replacement drawings showing amended figures, without markings, in compliance with 37 CFR 1.84 are required.
 - C. Other _____.
- 4. Amendments to the claims:
 - A. A complete listing of all of the claims is not present.
 - B. The listing of claims does not include the text of all pending claims (including withdrawn claims).
 - C. Each claim has not been provided with the proper status identifier, and as such, the individual status of each claim cannot be identified. Note: the status of every claim must be indicated after its claim number by using one of the following status identifiers: (Original), (Currently amended), (Canceled), (Previously presented), (New), (Not entered), (Withdrawn) and (Withdrawn-currently amended).
 - D. The claims of this amendment paper have not been presented in ascending numerical order.
 - E. Other: See Continuation Sheet.

For further explanation of the amendment format required by 37 CFR 1.121, see MPEP § 714 and the USPTO website at <http://www.uspto.gov/web/offices/pac/dapp/opla/preonnotice/officenflyer.pdf>.

TIME PERIODS FOR FILING A REPLY TO THIS NOTICE:

1. Applicant is given no new time period if the non-compliant amendment is an after-final amendment or an amendment filed after allowance. If applicant wishes to resubmit the non-compliant after-final amendment with corrections, the entire corrected amendment must be resubmitted within the time period set forth in the final Office action.
2. Applicant is given one month, or thirty (30) days, whichever is longer, from the mail date of this notice to supply the corrected section of the non-compliant amendment in compliance with 37 CFR 1.121, if the non-compliant amendment is one of the following: a preliminary amendment, a non-final amendment (including a submission for a request for continued examination (RCE) under 37 CFR 1.114), a supplemental amendment filed within a suspension period under 37 CFR 1.103(a) or (c), and an amendment filed in response to a Quayle action.

Extensions of time are available under 37 CFR 1.136(a) only if the non-compliant amendment is a non-final amendment or an amendment filed in response to a Quayle action.

Failure to timely respond to this notice will result in:

Abandonment of the application if the non-compliant amendment is a non-final amendment or an amendment filed in response to a Quayle action; or

Non-entry of the amendment if the non-compliant amendment is a preliminary amendment or supplemental amendment.



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/688,757	10/20/2003	Yu-An Chang		1993
7590	12/02/2005			
Yu-An Chang, Ph.D. 3631 Hamilton Street Irvine, CA 92614			EXAMINER	
			PEZZUTO, HELEN LEE	
			ART UNIT	PAPER NUMBER
			1713	

DATE MAILED: 12/02/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

femorofemoral artery implant, femoral-popliteal artery implant, femoro-tibial artery implant, fibular artery implant, plantar artery implant, dorsalis-pedis artery implant, arterial-venous fistulae, and venous implant, etc.

7. (Currently Amended) The drugs of claim 6 can be anti-coagulant drugs, anti-cancer drugs, Vascular Endothelial Growth Factor (VEGF) and/or Platelet Derived Growth Factor (PDGF) which include, but not limited to heparin, Taxol, and wherein said angiogenesis factor is selected from the group consisting of VEGF, VEGF 2, bFGF, VEGF121, VEGF165, VEGF189, VEGF206, PDGF, PDAF, TGF-B, PDEGF, PDWHF, etc.
8. (Currently Amended) The bio-compatible surface processed copolymers can covalently attached with cells from specific tissue or cell lines to create special biological effects, such as endothelium cells to reduce blood activation, and other unwanted or harmful biological activities.

10

15

20

25